Acino has acquired six prescription brands from Aspen Pharmacare for over R1.8 billion to enhance its South African healthcare portfolio.

Target Information

Acino has successfully completed its acquisition of six South African prescription brands from Aspen Pharmacare Holdings Limited for more than R1.8 billion (€105 million). This strategic move strengthens Acino's presence in South Africa's healthcare market and aligns with its commitment to being a Level 1 broad-based black economic empowerment (BBBEE) entity.

The acquired brands include Trustan®, Altosec®, Zuvamor®, Ciavor®, Grantryl®, and Aspen Granisetron®. To ensure continuous patient access to these medications, Acino and Aspen have entered into a seven-year manufacturing and supply agreement, allowing Aspen to supply the manufactured products to Acino. The acquisition bolsters Acino's portfolio in key therapeutic areas such as gastroenterology, erectile dysfunction, and cardiovascular disease.

Industry Overview

The healthcare industry in South Africa has witnessed significant growth, driven by increasing demand for high-quality medications and changing patient preferences. The co